Adaptimmune stock plunges after announcing Nasdaq delisting plans
WESTLAKE VILLAGE, Calif. - Turn Therapeutics (TTRX), a clinical-stage biotechnology company with a market capitalization of $182 million, announced Tuesday the appointment of Arthur Golden to its Board of Directors. Golden brings over 40 years of experience in corporate law, governance, and strategic advisory work. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 3.2, though it faces profitability challenges with negative EBITDA of $2.7 million in the last twelve months.
Golden currently serves as Senior Counsel at Davis Polk & Wardwell LLP, where he previously spent more than four decades as a partner. He recently completed a 24-year tenure as a Director at Emerson Electric, where he chaired the Corporate Governance and Finance Committees and served on the Executive Committee.
His expertise spans multiple sectors including healthcare, pharmaceuticals, consumer, industrial, and technology, with particular focus on mergers and acquisitions, regulatory affairs, and shareholder engagement.
"Arthur’s appointment adds a strong layer of governance, legal, and strategic experience to our Board as we advance Turn’s late-stage programs and expand our commercial reach," said Bradley Burnam, CEO of Turn Therapeutics, according to the company’s press release.
Turn Therapeutics develops products for dermatology, wound care, and infectious disease. The company has received three FDA clearances for its wound and dermatology formulations and is advancing clinical programs in eczema and onychomycosis. Trading near its 52-week low, the stock shows high price volatility - one of several key insights available through InvestingPro, which offers 5 additional exclusive tips about the company’s financial health and market position.
Golden holds a JD from New York University School of Law and a BS in Mathematics from Rensselaer Polytechnic Institute, where he is Chairman Emeritus of the Board of Trustees.
The information in this article is based on a company press release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.